Lessons Learned From the ACURATE IDE Trial for Transcatheter Aortic Valve Replacement
Bibliographic record
Abstract
The recent voluntary withdrawal of the ACURATE neo2 transcatheter aortic valve replacement device by Boston Scientific offers a compelling case study in the complex interplay of device design, clinical evidence, regulatory requirements, and market dynamics in modern structural heart interventions. Despite promising performance in European and Canadian registries, the ACURATE neo2 valve failed to demonstrate non-inferiority compared with commercially available balloon-expandable and self-expanding platforms in the pivotal ACURATE IDE randomized controlled trial. These results, coupled with introduction of a new regulatory requirements by the European notified body ultimately led to the global discontinuation of the platform. This review critically examines the technological characteristics of ACURATE neo2, compares it with other leading TAVR devices, and explores the potential reasons-ranging from clinical to strategic-that may have led to its market exit. Emphasis is placed on the role of randomized trials in assessing new structural therapies, including a discussion of methodological challenges and opportunities for adaptive trial designs. A structured comparison of device features and withdrawal rationales is also provided, highlighting lessons relevant to clinicians, regulators, and industry stakeholders. Ultimately, the ACURATE neo2 experience underscores the need for robust validation strategies, procedural standardization, and adaptive development pathways in a saturated and high-stakes market. Lessons learned from this platform should inform future innovation in TAVR and broader cardiovascular device development.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.007 | 0.011 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.002 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.002 | 0.002 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".